TABLE 4.

Comparison of hrHPV and HPV genotype detection results, ranked hierarchically according to cancer risk, by cobas HPV and AHPV tests^a

AHPV result by type and oncogenic risk	cobas result by HPV type				Total
	HPV16 positive	HPV18 positive	Other 12 hrHPV positive	hrHPV negative
HPV16 positive
No.	89	1	2	0	92
% of total	9.0	0.1	0.2	0.0	9.3
No. CIN2+	36	0	1	0	37
% CIN2+	38.3	0.0	1.1	0.0	39.4
HPV18/45 positive
No.	1	32	18	1	52
% of total	0.1	3.2	1.8	0.1	5.3
No. CIN2+	1	8	2	1	12
% CIN2+	1.1	8.5	2.1	1.1	12.8
Other 11 hrHPV positive
No.	12	3	228	27	270
% of total	1.2	0.3	23.1	2.7	27.3
No. CIN2+	3	0	30	2	35
% CIN2+	3.2	0.0	31.9	2.1	37.2
hrHPV negative
No.	11	7	44	512	574
% of total	1.1	0.7	4.5	51.8	58.1
No. CIN2+	0	1	2	7	10
% CIN2+	0.0	1.1	2.1	7.4	10.6
Total
No.	113	43	292	540	988
% of total	11.4	4.4	29.6	54.7	100.0
No. CIN2+	40	9	35	10	94
% CIN2+	42.6	9.6	37.2	10.6	100.0

^acobas separately detects HPV16 and HPV18 individually and concurrently with detection of a pool of 12 other hrHPV genotypes. AHPV GT separately detects HPV16 individually and HPV18 and HPV45 (HPV18/45) as a pool sequentially following positive testing for pool of 14 hrHPV genotypes. Presented is the number positive and percent of total samples tested positive of each paired result, and the number and the percentage of cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+).